PPT-Clinical Approaches to IPF:

Diagnosis and Monitoring Kevin R Flaherty MD MS   Associate Professor Pulmonary and Critical Care Medicine University of Michigan Health System Ann Arbor Michigan Faculty Disclosure . Dr. Abdelhaleem Bella. Assistant Professor of Medicine, Dammam University. Consultant Pulmonologist ,King Fahad Hospital of the University.. Layout of the Presentation. DPLD : A&C . ILD. IIP IPF. (ILD). Mike McFarlane (CT1). 12/5/12. SLIME. What we’ll cover. Definition. Different types of ILD. Pathophysiology. Presentation. Investigations. Management. Prognosis. Clinical Scenario. Summary. What we won’t.... Trials and Treatments. Craig Thurm, MD. Director, Pulmonary Medicine. Director, Pulmonary Fellowship. Medical Director. , . Respiratory . Care. Jamaica Hospital Medical Center. Disclosure of Relevant . Comorbidities and Complications. FACULTY. Title. Affiliation. Learning Objectives. Identify approaches to IPF management that are covered in current . guidelines. , taking into account the strength of relevant . PULMONARY FIBROSIS. 1. By: . Dr.Bidhi. . Chand. Junior Resident Pulmonary Medicine. INTERSTITIAL PULMONARY FIBROSIS. ATS Definition. . Interstitial Pulmonary Fibrosis is defined as a specific form of chronic . PULMONARY FIBROSIS MANAGEMENT STRATEGIES I. NOVEMBER 13, 2015. Pharmacologic therapy. Disclosures. Research Grants. Roche (. InterMune. ). Scientific Advisory Board . Roche (. InterMune. ). Boehringer. Discussing Prognosis &. Goals of Care. Sonye K. . Danoff. , MD, . PhD. PULMONARY FIBROSIS. : WHAT AND . WHY. November 13, 2015. No conflict of interest relevant to this presentation. Objective of this talk. . honeycombing. on HRCT. Case 1 | Demosthenes Bouros, Vasilios . Tzilas. | University of Athens. CASE OVERVIEW. 0. 2. A 76-year-old male . patient. . presented. . with. progressive . exertional. . Content. Importance. . of. . early. . diagnosis. . Initial . clues. . to. . suspect. IPF . Guidelines for Diagnosis. Diagnostic algorithm for IPF. . Exclusion of other known causes . Other tests and tools . 56-year-old Hispanic female with a family history of aortic aneurysm underwent a routine chest CT to assess her aorta. No respiratory symptoms. Medical history . h/o SVT. Type 2 diabetes mellitus. Hypertension. (. P. ulmonary Fibrosis . I. dentification: . L. essons for . O. ptimizing . T. reatment) is a national education initiative driven by The France Foundation, an ACCME-accredited . provider. Education focuses . January 2021. Summary - orvepitant first in class/category, novel treatment for debilitating chronic cough associated with the terminal orphan condition idiopathic pulmonary fibrosis. The NeRRe management team recently sold KaNDy Therapeutics to Bayer in a deal valued >$1b. When using our slides, please retain the source attribution:. These slides may not be published, posted online, or used in commercial presentations without permission. . Please contact . pce@practicingclinicians.com. for Fibrosis & Oncology. Corporate Presentation – April 2021. Disclaimer. This document has been prepared by Nuformix plc (the "Company") and is being . made available for the sole purpose of providing the recipients with background information about the Company. It.